Dr. Alice Erwin is an independent scientific consultant, providing consultation on antibacterial drug discovery to academic and industrial research groups. Her scientific research over the past forty years has revolved around the structure and function of bacterial membranes, with particular interest in the contribution of lipopolysaccharides to both the pathogenesis and the intrinsic antibiotic resistance of Gram-negative bacteria.
She held senior positions in antibiotic discovery programs at PathoGenesis Corporation, Chiron Corporation, and Vertex Pharmaceuticals. She is an author of over forty research publications, review articles and book chapters. Alice is a member of the Editorial Board of Antimicrobial Agents & Chemotherapy and has served on many NIH grant review panels. She is a subject matter expert for CARB-X and is on the advisory boards for CC4CARB (NIAID-funded Chemistry Center for Combating Antibiotic Resistant Bacteria) and PACE (Pathways to Antimicrobial Clinical Efficacy).